RFP: Research on Diagnostic and Treatment of Invasive Mold Disease Grant

RFP: Research on Diagnostic and Treatment of Invasive Mold Disease Grant

Status: ACTIVE
Funder: Pfizer, Inc.
Amount: Up to US $80,000
Last Updated: April 16, 2025

Summary

This grant opportunity from Pfizer focuses on improving the diagnosis and treatment of Invasive Mold Disease (IMD), particularly in China. It encourages innovative projects that address clinical unmet needs, enhance early diagnosis, and optimize antifungal treatments to improve patient outcomes. With a funding range of up to $80,000 and a total budget of $434,000, projects can span a maximum of three years, aiming to elevate healthcare professionals' awareness and management of IMD.

Overview

Note: grant requests for drug/compound are not in scope of this RFP. Pfizer will not supply formulated study drug nor pure substance. Geographic Scope/Location of Project China Project Types and Area of Interest Potential applicants are encouraged to identify and address the clinical unmet needs for the diagnostic and treatment of invasive mold disease (IMD) to early identify suspicious IMD patients, early kick off antifungal treatment and give appropriate antifungal drugs to improve patient outcomes and the prognosis of IMD, reduce treatment relevant AE and improve outcomes. Also leverage healthcare professionals’ awareness and management of IMD. Funding Range and Project Length Individual projects requesting up to $80,000 will be considered. The estimated total available budget related to this RFP is $434,000. Maximum project length is 3 years.Award amounts include direct costs, institutional overhead costs (capped at 28% per Pfizer policy), and indirect costs.

Eligibility

We've imported the main document for this grant to give you an overview. You can learn more about this opportunity by visiting the funder's website.